⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL357391 | 1.00 | — | — | |
| SCHEMBL477720 | 1.00 | — | — | |
| SCHEMBL765922 | 0.78 | — | — | |
| SCHEMBL533226 | 0.78 | — | — | |
| SCHEMBL4495282 | 0.75 | — | — | |
| SCHEMBL1450906 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL28282660 | 0.75 | — | — | |
| SCHEMBL4447966 | 0.75 | — | — | |
| Methyl Alcohol SCHEMBL365291 | 0.75 | — | — | |
| SCHEMBL9476213 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200283439-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | AbbVie Deutschland GmbH & Co. KG (DE) | 2020-09-10 | — | — | US | disclosed |
| EP-3636651-A1 | HEXAHYDROPYRAZINOBENZ- OR -PYRIDO-OXAZEPINES CARRYING AN OXYGEN-CONTAINING SUBSTITUENT AND USE THEREOF IN THE TREATMENT OF 5-HT2C-DEPENDENT DISORDERS | AbbVie Deutschland GmbH & Co. KG (DE) | 2020-04-15 | — | — | EP | disclosed |
| US-20190071443-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-03-07 | — | — | US | disclosed |
| US-20190048007-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-02-14 | — | — | US | disclosed |
| US-20180339996-A1 | HEXAHYDROPYRAZINOBENZ- OR -PYRIDO-OXAZEPINES CARRYING AN OXYGEN-CONTAINING SUBSTITUENT AND USE THEREOF IN THE TREATMENT OF 5-HT2C-DEPENDENT DISORDERS | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-11-29 | — | — | US | disclosed |
| US-10118926-B2 | Tricyclic quinoline and quinoxaline derivatives | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-11-06 | — | — | US | disclosed |
| US-10100048-B2 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-10-16 | — | — | US | disclosed |
| EP-3351543-A1 | 1-(QUINOLIN-4-YL)-3-(6-(TRIFLUOROMETHYL)-PYRIDIN-2-YL)UREA AND 1-(QUINOLIN-4-YL)-3-(6-(TRIFLUOROMETHYL)-PYRAZINE-2-YL)UREA DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3 (GSK-3) INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-07-25 | — | — | EP | disclosed |
| US-9994568-B2 | Tricyclic quinoline and quinoxaline derivatives | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-06-12 | — | — | US | disclosed |
| EP-3143023-B1 | OXINDOLE COMPOUNDS CARRYING A CO-BOUND SPIRO SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES | ABBVIE DEUTSCHLAND (DE) | 2018-04-11 | — | — | EP | disclosed |
| EP-1812416-A1 | ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE SUBSTITUTED AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MADULATION OF THE DOPAMINE D3 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2007-08-01 | — | — | EP | disclosed |
| EP-1809598-A1 | AMINOMETHYL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2007-07-25 | — | — | EP | disclosed |
| EP-1807392-A1 | 6-AMINO(AZA)INDANE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECPTOR | Abbott GmbH & Co. KG (DE) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006040178-A9 | ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE SUBSTITUTED AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MADULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007006566-A1 | PYRIDAZINE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006040177-A1 | 6-AMINO(AZA)INDANE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECPTOR | ABBOTT GMBH & CO.KG (DE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006040180-A1 | AMINOMETHYL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006040182-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006040176-A1 | AZABICYCLOHEPTYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006040178-A1 | ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE SUBSTITUTED AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MADULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO.KG (DE) | 2006-04-20 | — | — | WO | disclosed |